PHILADELPHIA, May 29, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Methylphenidate Hydrochloride Extended Release (ER) tablets USP (CII) in 18 ...

US regulatory officials say they have identified not one but two supposed generic copies of the attention deficit hyperactive disorder (ADHD) treatment drug Concerta that have failed to demonstrate ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. (Bloomberg) — Shortages of ADHD medications that started ...

An internal US Food and Drug Administration (FDA) re-examination of previously submitted data has raised concerns that two generic medications used to treat attention ...

The US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) on Tuesday proposed withdrawing two generic versions of Janssen’s extended-release attention deficit ...

Add Yahoo as a preferred source to see more of our stories on Google. Supply from drugmakers for the stimulant medications most commonly prescribed for ADHD are still falling short of demand, the Food ...

Dr. Reddy’s is offering methylphenidate hydrochloride extended-release tablets, in dosage strengths of 18 mg, 27 mg, 36 mg and 54 mg. The product is the generic of Janssen’s Concerta (methylphenidate ...

Q: I was delighted to read about Food and Drug Administration concerns regarding generic Concerta. My prescription insurance is going to an essentially generic-only pricing system that will push the ...

Two generic versions of the attention-deficit/hyperactivity disorder drug Concerta may not work as effectively as the brand-name product does, the U.S. Food and Drug ...

termed "ascending dose," was specifically designed to avoid acute tolerance, which is believed to be the cause of the diminished effectiveness of intermediate-acting methylphenidate preparations ...

STAMFORD, Conn.--(BUSINESS WIRE)--Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application ...